Featured Trial:
Brain Cancer Imaging

Featured Trial:
Lung Cancer Treatment

Featured Trial:
Colorectal Cancer Treatment

Featured Trial:
Melanoma Imaging

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

December 4, 2024

Categories

News Stories

Upfront treatment and early intervention to get attention at ASH 2024, including mantle cell lymphoma with the striking results of study EA4151

November 26, 2024

Categories

News Stories

WATCH: David Schiff discusses the striking survival improvement for patients with low-grade brain tumors found in study E3F05

November 26, 2024

Categories

Announcements

The November 2024 News from ECOG-ACRIN blog is now available

November 25, 2024

Categories

Press Releases

Press Release: Clinical trial finds that adding the chemotherapy pill temozolomide to radiation therapy improves survival in adult patients with a slow-growing type of brain tumor

November 25, 2024

Categories

Press Releases

Press Release: ECOG-ACRIN adds a late-breaking abstract to its ASH 2024 presentation line-up

November 22, 2024

Categories

Press Releases

Press Release: ECOG-ACRIN appoints seven researchers to scientific committee leadership positions

October 30, 2024

Categories

News Stories

ECOG-ACRIN and Caris partner to learn more from the TAILORx trial

October 30, 2024

Categories

News Stories

Using the geriatric assessment to actualize goal-concordant care (with EA2186/GIANT study chair Dr. Efrat Dotan)

October 30, 2024

Categories

News Stories

WATCH: Behind the ECOG-ACRIN E1910 trial with lead investigator Dr. Mark Litzow

Posts

ECOG-ACRIN Cancer Research Group Follow 8,199 6,373

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

2h 1950979914049388906

Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://bit.ly/ea5221-achieve cc: @BalazsHalmosMD @efratdotan @CPresGeriOncMD

Reply on Twitter 1950979914049388906 Retweet on Twitter 1950979914049388906 0 Like on Twitter 1950979914049388906 0 Twitter 1950979914049388906

ECOG-ACRIN Cancer Research Group @eaonc ·

4h 1950949723524710756

.@michael_lidsky of @DukeSurgOnc and @DukeCancer is leading EA2222/PUMP, a randomized phase 3 study for patients with #Colorectal liver metastases. Learn more: https://bit.ly/ea2222-pump cc : @CCAlliance, @LiverUSA

Reply on Twitter 1950949723524710756 Retweet on Twitter 1950949723524710756 2 Like on Twitter 1950949723524710756 4 Twitter 1950949723524710756

ECOG-ACRIN Cancer Research Group @eaonc ·

6h 1950919538280632692

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck (#HNSCC) that has come back after initial therapy. Learn more: https://bit.ly/ea3191-study #HeadAndNeckCancer #HNCA

Reply on Twitter 1950919538280632692 Retweet on Twitter 1950919538280632692 0 Like on Twitter 1950919538280632692 1 Twitter 1950919538280632692

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).